MedPath

Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD

• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.

Adenosine antagonists are emerging as potential therapeutics for a range of diseases, with several companies reporting promising clinical trial data. These compounds work by blocking adenosine receptors, modulating physiological processes such as sleep regulation, cardiovascular function, and immune response. Recent studies suggest that adenosine antagonists could enhance anti-tumor immune responses and offer new treatment options for conditions like cancer and COPD.

Advancements in Adenosine Antagonist Development

DelveInsight’s 'Adenosine Antagonists Pipeline Insight 2024' report highlights a robust pipeline with over 10 active players developing more than 12 adenosine antagonists. Key companies such as Arcus Biosciences, Corvus Pharmaceuticals, and iTeos Therapeutics are evaluating new drugs to improve treatment outcomes.

Clinical Trial Highlights

  • Corvus Pharmaceuticals: In November 2024, Corvus Pharmaceuticals announced data highlighting the potential of ciforadenant to overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer.
  • iTeos Therapeutics: In October 2024, iTeos Therapeutics presented preclinical and clinical data from inupadenant at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024.
  • Palobiofarm: On September 9, 2024, Palobiofarm announced positive top-line results in a Phase II trial of PBF-680 in patients with moderate-to-severe COPD.
  • Arcus Biosciences: In June 2024, Gilead Sciences and Arcus Biosciences shared new data from a Phase Ib/II study (ARC-9) evaluating etrumadenant plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy, and bevacizumab in third-line metastatic colorectal cancer.

Adenosine Antagonists in Oncology

In oncology, adenosine antagonists are being explored for their potential to enhance anti-tumor immune responses. Tumors often elevate extracellular adenosine levels to suppress the activity of T cells and natural killer cells, thereby evading immune surveillance. By blocking adenosine receptors, particularly A2A and A2B, these antagonists can restore the immune system's ability to recognize and attack cancer cells. This strategy is being investigated in combination with immune checkpoint inhibitors to improve outcomes in cancer immunotherapy.

Pipeline Therapies

Several adenosine antagonists are currently in various stages of clinical development:
  • Etrumadenant (Arcus Biosciences): Phase II trials for colorectal cancer, non-small cell lung cancer, pancreatic cancer, and rectal cancer.
  • Ciforadenant (Corvus Pharmaceuticals): Phase II trials for renal cell carcinoma.
  • Inupadenant (iTeos Therapeutics): Phase II trials for non-small cell lung cancer.
  • PORT-6/PORT 7 (Portage Biotech): Phase I/II trials for non-small cell lung cancer, prostate cancer, and renal cell carcinoma.
  • PBF-680 (Palobiofarm): Phase II trial for COPD.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved

The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.
Key companies like Boehringer Ingelheim and Idorsia Pharmaceuticals are advancing novel therapies to improve outcomes post-myocardial infarction.

Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape

The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.
A pivotal clinical trial revealed transformative findings poised to change the standard of care for children with acute lymphoblastic leukemia (ALL), marking a milestone in pediatric oncology.

Targeted Alpha Therapy Shows Promise in Expanding Cancer Treatment Landscape

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.
The FDA approval of Xofigo in 2013 for advanced prostate cancer marked a pivotal moment, spurring research into TAT for various solid tumors and hematological malignancies.

Antisense Oligonucleotide Therapies Advance in Genetic Medicine

Ionis Pharmaceuticals, a pioneer in antisense oligonucleotide (ASO) drugs, priced a $500 million IPO to fund clinical programs and commercial launches.
Isarna Therapeutics' lead candidate, ISTH0036, targeting TGF-β, shows promise in Phase 2 trials for wet AMD and DME, major ophthalmic conditions.

Thrombocytopenia Treatment Market Shows Promising Growth with Novel Therapies and Clinical Trials

The thrombocytopenia market is experiencing significant growth, driven by the introduction of novel therapies and ongoing clinical trials.
Key players like Sanofi, Takeda, and Amgen are actively involved in developing and marketing treatments for various types of thrombocytopenia.

Antibody-Drug Conjugates Market Surpasses $10 Billion, Driven by Lung and Breast Cancer Therapies

The antibody-drug conjugates (ADCs) market has exceeded US$10 billion in 2023, demonstrating its commercial viability in cancer therapeutics.
Lung cancer is witnessing the most extensive ADC development with over 60 candidates in clinical trials, addressing a high unmet medical need.

Tetanus Clinical Trial Pipeline Shows Promise with 20+ Drugs in Development

The tetanus clinical trial landscape is robust, featuring over 20 active players developing novel therapies to combat this severe bacterial infection.
Key pharmaceutical companies like GC Pharma and KM Biologics are advancing tetanus drugs, including GC 3111A and KD-370, through various clinical trial phases.

Viva Biotech Portfolio Companies Achieve Clinical Milestones in Diabetes, Gout, Obesity, Cancer, and Stroke

Seraxis received FDA IND allowance for SR-02, a stem cell-derived islet replacement therapy, marking a potential functional cure for insulin-requiring diabetes.
Arthrosi Therapeutics' AR882, co-developed with ApicHope, showed promising Phase II results for gout treatment, achieving significant uric acid reduction compared to Febuxostat.

Adrenoleukodystrophy: Emerging Therapies Show Promise in Clinical Trials

Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.
Key emerging therapies include ABX-002 (Autobahn Therapeutics), VK0214 (Viking Therapeutics), and SBT101 (SwanBio Therapeutics), among others, targeting various aspects of the disease.

Antibody-Drug Conjugates for Cancer Show Promise with Multiple FDA Approvals Anticipated by 2027

The cancer antibody-drug conjugate (ADC) market is experiencing substantial growth, driven by the demand for targeted therapies that improve efficacy and reduce side effects.
Over 600 ADCs are currently in clinical trials, with more than 20 in Phase 3, indicating a robust pipeline of potential new cancer treatments.

Reference News

[1]
Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ - GlobeNewswire
globenewswire.com · Dec 9, 2024

Adenosine antagonists market growth driven by R&D in neurodegenerative diseases, oncology, and cardiovascular disorders....

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy